Mayne Pharma reports unaudited Q4 and FY26 results
Filed with ASX · · 6 pages · English
Mayne Pharma Group Ltd. on 6ix
Story so far
Earlier from Mayne Pharma
- Mayne Pharma receives $14.4m for legal costs from Cosette
- Court awards MYX $13.27m for legal costs from Cosette
- Mayne Pharma reports unaudited 3Q FY26 results
- S&P DJI Announces March 2026 Quarterly Rebalance
- Mayne Pharma management changes
Later from Mayne Pharma
- Mayne Pharma to present at the 20th Bioshares Summit
- Non-Executive Director appointment
- Notification regarding unquoted securities - MYX
- Notification of cessation of securities - MYX
- Mayne Pharma Bioshares Summit Presentation
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma